A Great Talk from Our Coordinator Rafael De La Torre at the International Workshop on "Therapeutic Perspectives for Intellectual Disability in Down Syndrome " A great thanks to #T21 Italian TaskForce for this opportunity! #hadea#icodproject#aelisfarma#DS#IMIM
A great honor to participate as Italian Deputy for IHI network to the meeting at our Senate of the Republic about “Science for all" !! A Great Occasion to discuss also about dissemination activities for DS families in our European ICOD Project A great Thanks to #Esperia#HaDEA
On #WorldDownSyndromeDay, discover how EU-funded research is contributing to enhancing our understanding of Down syndrome and improving the cognitive development, autonomy and quality of life of people living with this condition.
🔗https://t.co/Ap9UwNFqNl
#H2020
#WorldDownSyndromeDay
AEF0217 : The first patient first visits in our Phase 2B clinical trial were completed in December 2025, marking the successful operational launch of the study. Today, screening and recruitment are actively underway across participating centres in Europe.
We will wait with our ICOD coordinator Rafael De La Torre tomorrow at 18,00 for the T21RS | Webinar 27 | The European ICOD project: new evidence for DS families!!
Thank you #T21RS Education Committee,#IMIM#hadea
See you on ZOOM
https://t.co/j14z445AFn
🧬 International Rare Disease Day – Feb 28
At Aelis Farma, we are convinced that therapeutic innovation in rare diseases also requires exploring new biological mechanisms.
“Therapeutic Perspectives for Intellectual Disability in Down Syndrome”.
Workshop promosso dall’AIPD – Associazione Italiana Persone con Sindrome di Down, sezione di Potenza, in collaborazione con la Task Force Italiana sulla Trisomia 21.
Happy to share our third publication of @ICOD_Project where we demonstrate that low IL-18 free levels contribute with high TNF-alfa and reduced TGF-β1 plasma levels to cognitive decline in Down syndrome and also suggest news target to treat cognitive decline in DS!! #Hadea#IMIM
Happy to share our third publication of @ICOD_Project where we demonstrate that low IL-18 free levels contribute with high TNF-alfa and reduced TGF-β1 plasma levels to cognitive decline in Down syndrome and also suggest news target to treat cognitive decline in DS!! #Hadea#IMIM
A great Advance for Our ICOD Project! Aelis Farma receives a positive opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down syndrome! @EU_HaDEA@EU_Commission@AelisFarma#IMIM#Icodproject#DS
https://t.co/PWfqsZXyEN
A Great Thanks to the Italian DS Task Force and this Round Table where we have had the opportunity to discuss with DS associations about Innovative drugs and Autonomy fir DS!! #Icodproject#DSTaskForce#IMIM#aelis#EuropeanUnion
Now in @NatureNeuro!
Thanks to a big collaborative effort, we have created a new tool to enhance mitochondrial function using DREADDS. This results in increased oxygen consumption and rescues cognitive deficits in cannabinoid- treated mice, and in Alzheimer and dementia models!
A strong immune system may be key to preventing Alzheimer’s disease. People with higher titers of anti-viral antibodies were less likely to have dementia. @NIHAging https://t.co/0fhxE7NqGf